BELGIUM – Belgian-based UCB has agreed to buy Zogenix Inc, a U.S. maker of drugs to treat seizures and rare diseases, for US$1.9 billion, expanding its portfolio to treat epilepsy.…
Read MoreBELGIUM – Belgian-based UCB has agreed to buy Zogenix Inc, a U.S. maker of drugs to treat seizures and rare diseases, for US$1.9 billion, expanding its portfolio to treat epilepsy.…
Read More